[go: up one dir, main page]

FR3000399B1 - Utilisation topique du laropiprant pour le traitement de la rosacee - Google Patents

Utilisation topique du laropiprant pour le traitement de la rosacee

Info

Publication number
FR3000399B1
FR3000399B1 FR1262973A FR1262973A FR3000399B1 FR 3000399 B1 FR3000399 B1 FR 3000399B1 FR 1262973 A FR1262973 A FR 1262973A FR 1262973 A FR1262973 A FR 1262973A FR 3000399 B1 FR3000399 B1 FR 3000399B1
Authority
FR
France
Prior art keywords
laropiprant
rosacea
treatment
topical use
topical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1262973A
Other languages
English (en)
Other versions
FR3000399A1 (fr
Inventor
Carine Rosignoli
Jerome Aubert
Jean Francois Fournier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to FR1262973A priority Critical patent/FR3000399B1/fr
Priority to PCT/FR2013/052324 priority patent/WO2014049300A1/fr
Publication of FR3000399A1 publication Critical patent/FR3000399A1/fr
Application granted granted Critical
Publication of FR3000399B1 publication Critical patent/FR3000399B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR1262973A 2012-09-28 2012-12-31 Utilisation topique du laropiprant pour le traitement de la rosacee Expired - Fee Related FR3000399B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1262973A FR3000399B1 (fr) 2012-12-31 2012-12-31 Utilisation topique du laropiprant pour le traitement de la rosacee
PCT/FR2013/052324 WO2014049300A1 (fr) 2012-09-28 2013-09-30 Utilisation topique du laropiprant pour le traitement de la rosacée

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1262973A FR3000399B1 (fr) 2012-12-31 2012-12-31 Utilisation topique du laropiprant pour le traitement de la rosacee

Publications (2)

Publication Number Publication Date
FR3000399A1 FR3000399A1 (fr) 2014-07-04
FR3000399B1 true FR3000399B1 (fr) 2015-03-27

Family

ID=47989208

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1262973A Expired - Fee Related FR3000399B1 (fr) 2012-09-28 2012-12-31 Utilisation topique du laropiprant pour le traitement de la rosacee

Country Status (2)

Country Link
FR (1) FR3000399B1 (fr)
WO (1) WO2014049300A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10933018B2 (en) 2015-10-30 2021-03-02 Timber Pharmaceuticals Llc Isotretinoin formulations and uses and methods thereof
FR3088543B1 (fr) 2018-11-21 2021-03-19 Waterdiam France Traitement des affections de la peau à base d’eau électrolysée

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952372A (en) 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
WO2006052798A2 (fr) * 2004-11-08 2006-05-18 Merck & Co., Inc. Methode de traitement des rougeurs pathologiques
ES2618352T3 (es) * 2006-06-16 2017-06-21 The Trustees Of The University Of Pennsylvania Antagonistas del receptor de prostaglandina D2 para el tratamiento de la alopecia androgenética
EP2480225A4 (fr) * 2009-07-31 2013-05-01 Panmira Pharmaceuticals Llc Préparations dermiques d'antagonistes du récepteur dp2

Also Published As

Publication number Publication date
FR3000399A1 (fr) 2014-07-04
WO2014049300A1 (fr) 2014-04-03

Similar Documents

Publication Publication Date Title
EP2932930A4 (fr) Instrument de traitement
EP3011515A4 (fr) Traitement de transactions vocales
EP2968208A4 (fr) Traitement de la cataplexie
EP2912462A4 (fr) Biomarqueur utilisable dans le traitement de l'anémie
EP2856331A4 (fr) Traitement stochastique
EP2906208A4 (fr) Traitement thérapeutique
EP2844346A4 (fr) Compositions pharmaceutiques pour traitement combiné
PL2852391T3 (pl) Układy do leczenia infekcji płuc
DK2879636T3 (da) Sårbandage
EP3288592A4 (fr) Utilisation de cannabidiol pour le traitement de spasmes infantiles
EP2870490A4 (fr) Traitement de trilatération amélioré
EP2920308A4 (fr) Traitement du cancer
BR112014031335A2 (pt) bloco de diagnóstico transacional
EP2995262A4 (fr) Instrument de traitement endoscopique
EP3025716A4 (fr) Substance pour le traitement ou le soulagement de la douleur
EP2868741A4 (fr) Liquide de traitement aqueux
EP2905027A4 (fr) Utilisation de mycobacterium brumae pour le traitement du cancer de la vessie
EP2830633A4 (fr) Thérapie combinée destinée au traitement du cancer
EP2544692A4 (fr) Utilisation de la tigécycline pour le traitement du cancer
EP2950976A4 (fr) Solutions de traitement pour découper, polir et colorer le béton
EP2861302A4 (fr) Utilisation de modulateurs de ccr5 dans le traitement du cancer
EP2817011A4 (fr) Traitement du cancer
HUE046508T2 (hu) Orvepitant krónikus viszketés kezelésére
EP2977356A4 (fr) Appareil de traitement de liquide
FR2993464B1 (fr) Pansement interface autoporte

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20160831